S
SOM Biotech
Biopharmaceutical company focused on the accelerated development of drugs for orphan indications through AI technology
About SOM Biotech
SOM Biotech is a clinical-stage biopharmaceutical company that leverages Artificial Intelligence (AI) to accelerate the discovery of therapies for unmet medical needs. The company operates in the healthcare and pharmaceutical sectors, focusing on developing treatments for rare and orphan diseases. SOM Biotech's business model revolves around using its proprietary AI-based drug discovery technology to identify and develop new therapeutic solutions more efficiently than traditional methods. This approach reduces the time and cost associated with research and development (R&D) processes. The company generates revenue through partnerships, licensing agreements, and the commercialization of its drug candidates. Key clients include pharmaceutical companies, healthcare providers, and research institutions. SOM Biotech has achieved significant milestones, such as positive Phase 2a clinical data for its drug candidate SOM3355 and receiving Orphan Drug Designation from the FDA. The company continues to innovate and expand its pipeline, aiming to bring effective treatments to patients faster.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Montcada i Reixac, Spain
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 75.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Core AI, Spinout, Tech for Biotech and Pharma, AI Drug Discovery
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning SOM Biotech.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| OtherOther financing | Jan 2021 | $0 | — | Monte Carlo Capital | — |
| EARLY VC✓Equity / VC | Mar 2019 | $7.7M | $220M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for SOM Biotech is 2K monthly website visits, up 53.8% over the last three months. SOM Biotech's team grew 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Monte Carlo Capital
Other known investors3 additional known investors
Biomedical Research Institute of Lleida
Universitat de Lleida
HTH
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SOM Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SOM Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.